Cost-effectiveness analysis of canagliflozin (CANA) versus...

Value in Health 2014 / 05 Vol. 17; Iss. 3

Cost-effectiveness analysis of canagliflozin (CANA) versus dapagliflozin (DAPA) as an add-on to metformin (MET) in patients with type 2 diabetes mellitus (T2DM) in the united states

Neslusan, C., Teschemaker, A., Martin, S., Willis, M., Johansen, P.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
17
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2014.03.1448
Date:
May, 2014
File:
PDF, 63 KB
english, 2014
Conversion to is in progress
Conversion to is failed